Navigation Links
Omeros Corporation Reports Third Quarter 2013 Financial Results
Date:11/7/2013

er 30, 2013, total (i.e., cash and non-cash) operating expenses, excluding the litigation expense, increased by $3.1 million compared to the same period in 2012. The increase was primarily due to the non-cash rent and stock-based compensation expenses of $3.2 million in 3Q 2013 compared to $576,000 in 3Q 2012. The remaining increases were related to conducting the company's Phase 1 clinical program evaluating OMS824, advancing our MASP-2 program, preparing the New Drug Application (NDA) and Marketing Authorization Application (MAA) for OMS302, planning for the commercial launch of OMS302 in the second half of 2014, and non-recurring legal expenses incurred in connection with the CCIC matter. These higher costs were partially offset by lower overall clinical trial expenses related to the completion of the company's OMS302 Phase 3 clinical program in January 2013 and the completion of the company's first OMS103HP Phase 3 clinical trial in arthroscopic partial meniscectomy patients in December 2012.

Total revenue for the quarter ended September 30, 2013 was $196,000 compared to $1.4 million for the same period in 2012. This decrease was primarily due to lower revenue recognized from the company's GPCR platform development funding agreement with Vulcan Inc. and its affiliate. While research continues under the company's GPCR program, no additional deferred revenue under the Vulcan agreement remains to be recognized after the first quarter of 2013.

For the quarter ended September 30, 2013, Omeros reported a net loss of $13.9 million, or $0.46 per share, inclusive of the above-referenced $3.2 million of non-cash charges equaling $0.11 per share, compared to a net loss of $13.3 million, or $0.51 per share, inclusive of the above-referenced $576,000 of non-cash charges equaling $0.02 per share, for the same period in 2012.

At September 30, 2013, Omeros had cash, cash equivalents and short-term investments of $9.0 million. On October 24, 2013, subseque
'/>"/>

SOURCE Omeros Corporation
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Omeros Announces Closing of $16.2 Million Registered Direct Offering of Common Stock
2. Omeros to Present at the 12th Annual Needham Healthcare Conference
3. Omeros Corporation Reports Fourth Quarter and Year-End 2012 Financial Results
4. Omeros Announces Enrollment in Phase 1 Clinical Trial Evaluating OMS824
5. Omeros to Present at the 19th Annual Newsmakers in the Biotech Industry Conference
6. Omeros Has Now Unlocked Over Half of the Class A Orphan GPCRs
7. Omeros Announces it has Unlocked 30 Percent of Class A Orphan GPCRs
8. Omeros Announces It Has Unlocked Over 20 Percent of Class A Orphan GPCRs
9. China Cord Blood Corporation to Report Second Quarter and First Half of Fiscal 2014 Financial Results
10. Attention Amarin Corporation plc Investors: Amarin Corporation plc Misled Investors According to a Newly Filed Class Action
11. General Patent Corporation Chairman and CEO Alexander Poltorak Joins Spherix Board Industry veteran and authority on patent law and valuation joins Spherix as director
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2014)... BLOOMINGTON, Ind. -- Chemists at Indiana University Bloomington ... in bricks-and-mortar fashion, a development with potential value ... as field-effect transistors and photovoltaic cells. , Their ... 3D Crystalline Solids and 2D Self-Assembled Crystals," has ... a journal of the Royal Society of Chemistry. ...
(Date:7/31/2014)... Graphite Metallizing Corporation announces GRAPHALLOY® bearings ... are uniquely suited to prevent loss of lubrication that ... high temperatures . , Recently, a manufacturer of ... at Graphite Metallizing to overcome problems with movement of ... pans containing blocks of powder mixture are loaded onto ...
(Date:7/31/2014)... (PRWEB) July 31, 2014 CollabRx, Inc. ... inform therapeutic decision-making in oncology, today announced that it ... 2014 to discuss the Company's financial results for the ... update about the business in the current fiscal year. ... beginning on Thursday, August 14, 2014, at 5 p.m. ...
(Date:7/31/2014)... Francisco, Calif. (PRWEB) July 31, 2014 ... newly diagnosed patients with an overview of the disease ... management of drug side effects, as well as updates ... “We’re grateful to Dr. Sandy Srinivas for organizing this ... survivor of kidney cancer. “Sandy and her colleagues have ...
Breaking Biology Technology:Chemists demonstrate 'bricks-and-mortar' assembly of new molecular structures 2Chemists demonstrate 'bricks-and-mortar' assembly of new molecular structures 3Graphite Metallizing Announces Bearings for High Temperature Oven Applications 2Graphite Metallizing Announces Bearings for High Temperature Oven Applications 3CollabRx, Inc. Schedules First Quarter Fiscal Year 2015 Financial Conference Call and Business Update 2
... deCODE genetics,(Nasdaq: DCGN ) today announced its ... 2008. A conference call to discuss the,quarter,s results, ... webcast live tomorrow, Friday, November 7, at 8:00am ... third quarter 2008 was $11.3 million, compared,to $22.2 ...
... NGX-4010 for management of pain associated ... with PHN, ... review for NGX-4010 ... NGSX ), a biopharmaceutical company focused on developing and,commercializing novel pain management ...
... While Public Relations has,long been used as a ... ability to reach consumers has never been greater. ... the traditional press,release as effective and low-cost methods ... was conducted by Best Practices, LLC to,identify what ...
Cached Biology Technology:deCODE genetics Announces Third Quarter 2008 Financial Results 2deCODE genetics Announces Third Quarter 2008 Financial Results 3deCODE genetics Announces Third Quarter 2008 Financial Results 4deCODE genetics Announces Third Quarter 2008 Financial Results 5deCODE genetics Announces Third Quarter 2008 Financial Results 6deCODE genetics Announces Third Quarter 2008 Financial Results 7deCODE genetics Announces Third Quarter 2008 Financial Results 8deCODE genetics Announces Third Quarter 2008 Financial Results 9deCODE genetics Announces Third Quarter 2008 Financial Results 10deCODE genetics Announces Third Quarter 2008 Financial Results 11deCODE genetics Announces Third Quarter 2008 Financial Results 12NeurogesX Reports Third Quarter 2008 Results 2NeurogesX Reports Third Quarter 2008 Results 3NeurogesX Reports Third Quarter 2008 Results 4NeurogesX Reports Third Quarter 2008 Results 5NeurogesX Reports Third Quarter 2008 Results 6NeurogesX Reports Third Quarter 2008 Results 7NeurogesX Reports Third Quarter 2008 Results 8NeurogesX Reports Third Quarter 2008 Results 9New Study Shares Best Practices in Biopharma Public Relations 2
(Date:7/31/2014)... adipocytes, or fat cells, are inherently different. Each of ... its own role in metabolism. In the human body, ... Its primary function is energy storage. On the other ... but are only found in a few places in ... special type of brown adipocytes, appear mixed with brown ...
(Date:7/31/2014)... studies have shown that marine noise can affect animal ... the Universities of Bristol and Exeter and the cole ... demonstrated that boat noise stops embryonic development and increases ... the sea slug Stylocheilus striatus used in ... away and later feed on toxic alga but this ...
(Date:7/30/2014)... epigenetic processes to regulate its genes, and adapt to ... of the genome regulation taking place in the truffle, ... Biology and illustrates how the truffle deals with ... authors say this may shed light on how traits ... (Tuber melanosporum), also known as Prigord truffles, have a ...
Breaking Biology News(10 mins):Hope for the overweight 2Boat noise impacts development and survival of sea hares 2How black truffles deal with the jumpers in their genome 2
... Fast development is often perceived as an advantage, ... readiness to cope with the challenges that it poses. ... and University of California, Santa Cruz, and published in ... the acceleration of developmental rate incurs potentially lethal physiological ...
... molding some snow into a ball and hurling it or ... can? New research from Indiana University and the University of ... readily learn to throw long distances. This research also suggests ... in a way critical to our very existence. ...
... N.C. Despite what you might have heard, genetic sequencing ... Duke University Medical Center have shown that functional tests are ... of sequencing studies as they relate to disease, using a ... patients to have many different traits. "Right now ...
Cached Biology News:Faster development might have its costs 2Faster development might have its costs 3IU study: Humans' critical ability to throw long distances aided by an illusion 2IU study: Humans' critical ability to throw long distances aided by an illusion 3Genetic sequencing alone doesn't offer a true picture of human disease 2Genetic sequencing alone doesn't offer a true picture of human disease 3
Angiotensin Converting Enzyme [Porcine Kidney, ACE, Peptidyl-dipeptidase A]...
Oven mesh sheets, large, 23 x 23cm, pack of 5...
Preparation Note: Prepared essentially by method of Singer, T.P., J. Biol. Chem., 174, 11 (1948). Quality Clarifier: Contains lipase Unit Definition: One unit will hydrolyze 1.0 μmole of p-ni...
... Analysis Note: Protein determined by Biuret ... 25 mM Tris-HCl, pH 7.6, 1 mM ... 2 Preparation Unit Definition: One unit ... per minute at pH 9.8 at 37 ...
Biology Products: